AIDX 20/20 Biolabs, Inc.
Company Analysis
Latest News
🟢 20/20 Biolabs is trading 9.63% up today after shareholders approved 500 million authorized shares
20/20 Biolabs is trading 9.63% up now at $0.51 after shareholders approved increasing authorized common stock from 50 million to 500 million shares. - The...
AIDX Stockholders Approve 10x Increase in Authorized Common Stock to 500 Million Shares
20/20 Biolabs, Inc. (AIDX) announced that its stockholders have approved a charter amendment to increase the number of authorized shares of its common stock...
🟢 20/20 Biolabs is trading 6% up today amid sector-driven biotech momentum
20/20 Biolabs is trading at $0.50 (+6.04%), with the move appearing primarily driven by sector momentum. - No new company-specific announcement, filing,...
🔴 20/20 Biolabs is trading 6.2% down today with no clear catalyst identified
20/20 Biolabs is trading 6.2% down at $0.46, reversing its September 16, 2026 close of $0.48, with no clear catalyst identified. - No company-specific...
🟢 20/20 Biolabs is trading 5% up today; catalyst unclear
20/20 Biolabs is trading 5.09% up now at $0.50, with no clear catalyst identified. - The move reverses September 15’s 8.59% decline and September 14’s 7.05%...
🔴 20/20 Biolabs is trading 5.55% down in pre-market with reconvened shareholder vote scheduled
20/20 Biolabs is trading 5.55% down at $0.45, extending recent declines after falling 8.59% on September 15 and 7.05% on September 14. - No new...
🔴 20/20 Biolabs, Inc. is trading 9.70% down
AIDX is trading at $0.47, down 9.70%.
🔴 20/20 Biolabs is trading 5% down today after Nasdaq cited sub-$1 price and equity shortfall
20/20 Biolabs is trading $0.50 (-5.18%) after Nasdaq cited a sub-$1 bid price and stockholders’ equity below the required $2.5 million threshold. • On...
🟢 20/20 Biolabs is trading 7.59% up today with no clear catalyst despite weaker markets
20/20 Biolabs is trading 7.59% up at $0.60, with no company-specific announcement or reliable news directly explaining the gain. - The move extends the...
🔴 20/20 Biolabs is trading 5.18% down today amid rate-related concerns ahead of Federal Reserve meeting
20/20 Biolabs is trading 5.18% down at $0.53, primarily amid global market weakness and rate-related concerns ahead of the Federal Reserve meeting. - It...
🔴 20/20 Biolabs is trading 6.11% down in pre-market; no clear company-specific catalyst identified
20/20 Biolabs is trading 6.11% down at $0.53 after closing at $0.56 on September 11, 2026; no clear company-specific catalyst dated September 14, 2026 was...
🟢 20/20 Biolabs is trading 6.16% up in pre-market with no clear catalyst identified
20/20 Biolabs is trading 6.16% up at $0.59 after rising from the September 11 close of $0.56; the pre-market gain remains unexplained. - No company-specific...
🟢 20/20 Biolabs is trading 10.64% up today amid broad market gains
20/20 Biolabs is trading at $0.60 (+10.64%) amid broad market strength after rebounding from the September 10 close of $0.54. • Major U.S. indexes are rising...
🟢 20/20 Biolabs is trading 7.36% up today amid broad market gains
20/20 Biolabs is trading at $0.58 (+7.36%) amid broad market gains. - On September 11, 2026, it is rebounding from the September 10 close of $0.54. - No fresh...
🟢 20/20 Biolabs is trading 12.9% up in pre-market as major index futures rise
20/20 Biolabs is trading 12.88% up now at $0.61, likely reflecting broader risk-on sentiment. - Rebounding from the September 10 close of $0.54. - No fresh...
AIDX Receives Nasdaq Non-Compliance Notice for Stockholders' Equity Requirement
20/20 Biolabs, Inc. (AIDX) received a notification from Nasdaq on September 3, 2026, indicating it is not in compliance with the minimum stockholders' equity...
🔴 20/20 Biolabs is trading 5.4% down today after hotter-than-expected producer inflation
20/20 Biolabs is trading 5.4% down at $0.53 amid broad market selling following hotter-than-expected producer inflation and rising concerns that the Federal...
🟢 20/20 Biolabs is trading 8% up today
20/20 Biolabs is trading 7.88% up now at $0.61, but no clear company-specific catalyst has been identified. - No company-specific announcement dated September...
AIDX Provides Business Update Highlighting FDA Engagement and Q2 Commercial Progress
AIDX (20/20 Biolabs, Inc.) provided a business update via an investor presentation, detailing recent preliminary discussions with the FDA for its OneTest...
🟢 20/20 Biolabs is trading 5.56% up today as XBI gains 2.75%
20/20 Biolabs is trading at $0.65 with a +5.56% gain, primarily amid biotech-sector strength. - Biotech stocks provided a supportive backdrop, with XBI up...